
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/drug-pricing-debate-in-washington-is-a-headache-for-pharma-11655463602
Listen to article
(2 minutes)
Big Pharma loves political gridlock. In fact, shares of pharmaceutical and biotechnology companies tend to outperform the broader market when Congress is divided.
With Republicans poised to flip control of the House in the midterm elections and President Biden’s “Build Back Better”—which included drug pricing reform—on life support, it seemed Big Pharma would soon be in the clear on tough action coming out of Washington.
Continue reading your article witha WSJ membership
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
WSJ Membership
Customer Service
Tools & Features
Ads
More
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

